Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Schöffski, Patrick; Woźniak, Agnieszka; Escudier, Bernard; Rutkowski, Piotr; Anthoney, Alan; Bauer, Sebastian; Šufliarský, Jozef; Herpen, Carla van; Линднер, Ларс; Grünwald, Viktor; Zakotnik, Branko; Lerut, Evelyne; Dębiec‐Rychter, Maria; Marréaud, Sandrine; Lia, Michela; Raveloarivahy, Tiana; Collette, Sandra; Albigès, Laurence

doi:10.1016/j.ejca.2017.10.014

Cited by 107 publications

(79 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… cMET inhibitors have shown activity in papillary RCC with cMET mutation or amplification [57]. Crizotinib or other cMET inhibitors such as cabozantinib appear as acceptable option instead of usual VEGF TKIs.…”

Section: Medical Treatment For Non-ccrccmentioning

confidence: 99%

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

et al. 2019

View full text Add to dashboard Cite

Section: Medical Treatment For Non-ccrccmentioning

confidence: 99%

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

et al. 2019

View full text Add to dashboard Cite

“…Two such drivers are alterations in MET, which are found in 17-33% of type 1 papillary and 7% of type 2 pRCCs [48], and mutations in the gene for fumurate hydratase, which result in the familial syndrome of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) that is associated with an aggressive variant of type 2 pRCC. Our review found the results of trials using MET inhibitors to be somewhat underwhelming for unselected patients with pRCC, but ORR for patients harboring MET mutations are as high as 50% and further study of biomarker-selected patients is needed [37][38][39][40]. Cabozantinib, an inhibitor of multiple tyrosine kinases including c-MET and VEGFR2, has demonstrated efficacy in metastatic ccRCC [49,50], but as of yet there are no published prospective studies evaluating its efficacy in nccRCC.…”

Section: Papillarymentioning

confidence: 98%

A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma

Osterman

Rose

2020

KCA

View full text Add to dashboard Cite

Introduction: There have been a number of recent advances in the management of advanced clear cell renal cell carcinoma (ccRCC). However, the majority of these studies excluded patients with non-clear cell RCC (nccRCC), and optimal management of nccRCC remains unknown. Materials and Methods: A systematic review of the literature was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to evaluate systemic treatment options in locally advanced or metastatic nccRCC between 2000-2019. Randomized controlled trials, single-arm phase II-IV trials, and prospective analyses of medication access programs were included. The primary outcome measures were progression free survival (PFS), overall survival (OS), and objective response rate (ORR). Results: A total of 31 studies were included in the final analysis. There was the highest level of evidence to support firstline treatment of nccRCC with sunitinib. Additional single-arm trials support the use of other vascular endothelial growth factor (VEGF) inhibitors with axitinib and pazopanib, as well as mammalian target of rapamycin (mTOR) inhibition with temsirolimus or everolimus +/-bevacizumab. Immune checkpoint inhibition has an emerging role in nccRCC, but optimal sequencing of available options is not clear. Prospective data to support the use of newer immunotherapy combinations are lacking. Treatment for collecting duct carcinoma remains platinum-based chemotherapy. Conclusions: The availability of randomized trials in nccRCC is limited, and most studies include outcomes for nccRCC as a group, making conclusions about efficacy by subtype difficult. This systematic review supports consensus guidelines recommending sunitinib or clinical trial enrollment as preferred first-line treatment options for nccRCC, but also suggests a more nuanced approach to management and new options for therapy such as immune checkpoint inhibition.

show abstract

“…The mPFS was 6.2 months in MET ‐driven PRCC and 1.4 months in MET ‐independent diseases ( P < 0.001). Crizotinib is an ALK inhibitor, but has affinity to MET kinase . Crizotinib was used in 23 type 1 PRCC patients, and four tumors had a MET mutation.…”

Section: Papillary Rccmentioning

confidence: 99%

Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas

Ito

2019

Int J of Urology

View full text Add to dashboard Cite

Abbreviations & Acronyms AA = anti-angiogenic ALK = anaplastic lymphoma kinase ARE = anti-oxidant responsive element ccRCC = clear cell renal cell carcinoma CDC = collecting duct carcinoma ChRCC = chromophobe renal cell carcinoma CR = complete response CTLA-4 = cytotoxic Tlymphocyte antigen 4 EV = everolimus FH = fumarate hydratase IMDC = International Metastatic Renal Cell Carcinoma Database Consortium INF-a = interferon-a IO drug = immuno-oncology drug ISUP = International Society of Urological Pathology LOH = loss of heterozygosity MET+ = MET mutation+ METÀ = MET mutationÀ MiT = microphthalmiaassociated transcription mOS = median overall survival mPFS = median progressionfree survival mPRCC = metastatic papillary renal cell carcinoma mRCC = metastatic renal cell carcinoma MSKCC = Memorial Sloan-Kettering Cancer Center mTORi = mammalian target of rapamycin inhibitor MTSCC = mutinous tubular and spindle cell carcinoma NA = not availableAbstract: There is still no standard treatment for non-clear cell renal cell carcinomas. Sunitinib is the most examined drug because of its effectiveness in retrospective studies and clinical trials, and is the preferred first-line drug in the National Comprehensive Cancer Network guideline. Temsirolimus is an option as a first-line drug, especially for poor-risk non-clear cell renal cell carcinoma patients. Everolimus, pazopanib, axitinib and nivolmab might also be viable options. Clinical trials are still required to gather evidence regarding non-clear cell renal cell carcinoma treatment. Because each non-clear cell renal cell carcinoma has a different genetic background and molecular features, specific treatment for each non-clear cell renal cell carcinoma should be established. From the results of a Japanese multicenter study, tyrosine kinase inhibitors might be better used for metastatic papillary renal cell carcinoma in both first-and second-line settings. Both tyrosine kinase inhibitors and mammalian target of rapamicin inhibitors are effective for metastatic chromophobe renal cell carcinoma, but the preferred first-line drug has not been determined. Platinum-based chemotherapies are currently recommended for metastatic collecting duct carcinoma, and anti-angiogenic drugs are effective in some cases. Tyrosine kinase inhibitors, especially sunitinib, appear to be effective for X11.2 translocation renal cell carcinoma among the microphthalmia-associated transcription family of translocation renal cell carcinomas. Evidence is still lacking regarding the treatment for other rare non-clear cell renal cell carcinomas. Appropriate sequential therapies using antivascular endothelial growth factor therapies, mammalian target of rapamicin inhibitors and immuno-oncology drugs should be established for each nonclear cell renal cell carcinoma. None declared. References 1 Ito K. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinoma. Int. J. Urol. 2019; 26: 868-77. 2 Teishima J, Inoue S, Hayashi T, Matsubara A. Current status of prognostic factors in ...

show abstract

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Cited by 107 publications

References 25 publications

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma

Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas

Contact Info

Product

Resources

About